Stockscreener 앱 받기
0.4902
0.88%
-0.0002
전일 마감가:
$0.49
열려 있는:
$0.5
하루 거래량:
156.28K
Relative Volume:
0.11
시가총액:
$91.34M
수익:
$8.95M
순이익/손실:
$-21.49M
주가수익비율:
-4.085
EPS:
-0.12
순현금흐름:
$-29.24M
1주 성능:
+21.43%
1개월 성능:
-1.26%
6개월 성능:
-44.81%
1년 성능:
-57.39%
1일 변동 폭
$0.4835
$0.505
1주일 범위
$0.402
$0.5138
52주 변동 폭
$0.3651
$1.3999
Lineage Cell Therapeutics Inc Stock (LCTX) Company Profile
명칭
Lineage Cell Therapeutics Inc
전화
510-871-4188
주소
2173 Salk Avenue, Suite 200, Carlsbad, CA
LCTX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
LCTX
Lineage Cell Therapeutics Inc
|
0.4902 | 91.34M | 8.95M | -21.49M | -29.24M | -0.12 |
|
VRTX
Vertex Pharmaceuticals Inc
|
496.15 | 122.76B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
610.58 | 61.38B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
619.89 | 36.37B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
255.65 | 30.12B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
251.44 | 24.70B | 3.81B | -644.79M | -669.77M | -6.24 |
Lineage Cell Therapeutics Inc Stock (LCTX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-08-20 | 개시 | Craig Hallum | Buy |
| 2022-11-02 | 개시 | Robert W. Baird | Outperform |
| 2022-06-14 | 개시 | B. Riley Securities | Buy |
| 2021-08-19 | 개시 | Noble Capital Markets | Outperform |
| 2021-03-31 | 개시 | Cantor Fitzgerald | Overweight |
Lineage Cell Therapeutics Inc 주식(LCTX)의 최신 뉴스
Lineage Cell Therapeutics Inc [LCTX] Shares Rise 5.57 % on Thursday - knoxdaily.com
Stem Cell Therapy Market Growth, Trends, & Key Insights | Global - openPR.com
LCTX’s Stock Market Pendulum: Swinging Between Gains and Losses - investchronicle.com
Lineage Cell Therapeutics and the Christopher & Dana Reeve Foundation Proudly Announce the 3rd Annual Spinal Cord Injury Investor Symposium - BioSpace
Lineage Cell Therapeutics and the Christopher & Dana Reeve Foundation Proudly Announce the 3 - Business Wire
-2.44 Fall Turns Lineage Cell Therapeutics Inc (LCTX) Into A Losing Stock For Investors - Marketing Sentinel
Market Recap: Lineage Cell Therapeutics Inc (LCTX)’s Negative Momentum, Closing at 0.41 - DWinneX
Lineage to Present at 2025 Eyecelerator Meeting Sponsored by the - GuruFocus
Lineage to Present at 2025 Eyecelerator Meeting Sponsored by the American Academy of Ophthalmology (AAO) - Business Wire
Revolutionary Eye Drug Delivery Methods: Lineage CEO Joins Elite Panel at Major Ophthalmology Conference - Stock Titan
Ernexa Therapeutics Stock Price, Quotes and Forecasts | NASDAQ:ERNA - Benzinga
BioTime, Inc. : CORRECTION - MarketScreener
BioTime, Inc. : BioTime Announces First Quarter 2012 Financial Results and Recent Corporate Accomplishments - marketscreener.com
Lineage Cell (LCTX) Reports Q4 Loss, Tops Revenue Estimates - MSN
BioTime Provides Business Update Including Information on AgeX, OncoCyte and Asterias - MarketScreener
Let’s Dive Into The Lineage Cell Therapeutics Inc (AMEX: LCTX) Stock Forecast. - Marketing Sentinel
LCTX Stock: A Comprehensive Analysis and Forecast - investchronicle.com
Weak Fundamental Momentum Sinks Lineage Cell Therapeutics Inc - Marketing Sentinel
LCTX stock touches 52-week low at $0.48 amid market challenges - Investing.com
Lineage Cell Therapeutics : Wave Life Sciences Announces Positive Data from FORWARD 53 Clinical Trial in DMD Including Significant Functional Benefit and Reversal of Muscle Damage after 48 Weeks of Dosing with WVE N531 - MarketScreener
Cell Therapy Manufacturing Market Demand, Growth and Future - openPR.com
It’s Worth A Gamble To Have A Position In Lineage Cell Therapeutics Inc (AMEX: LCTX) At $0.50. - Marketing Sentinel
LCTX stock touches 52-week low at $0.48 amid market challenges By Investing.com - Investing.com South Africa
Lineage Cell Therapeutics Inc (AMEX: LCTX) Shares Declined By -27.01% In One Month. - Marketing Sentinel
B. Riley Forecasts Lineage Cell Therapeutics Q1 Earnings - Defense World
B. Riley Issues Pessimistic Forecast for Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) Stock Price - Defense World
Lineage Cell Therapeutics: 2024 Financial Results and Strategic Progress - TipRanks
B. Riley Cuts Price Target on Lineage Cell Therapeutics to $3 From $4, Keeps Buy Rating - Marketscreener.com
HC Wainwright Weighs in on Lineage Cell Therapeutics Q1 Earnings - Defense World
Now Is The Time To Build A Position In Lineage Cell Therapeutics Inc (AMEX:LCTX) - Marketing Sentinel
Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) Receives Buy Rating from D. Boral Capital - Defense World
Cell Therapy Manufacturing Market Poised for Expansion Biotech - openPR
Dry AMD Market Expected to rise, 2034 | Alkeus Pharmaceuticals, Belite Bio, Aviceda Therapeutics, Johnson & Johnson Innovative Medicine, Allegro Ophthalmics, Lineage Cell Therapeutics - The Globe and Mail
Dry AMD Market Expected to rise, 2034 | Alkeus Pharmaceuticals, - openPR
Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) Receives “Buy” Rating from HC Wainwright - Defense World
Lineage Cell Therapeutics stock target cut to $3 by Craig-Hallum - Investing.com Australia
Lineage Cell Therapeutics Faces Uncertainty Amid New U.S. Administration’s Policies - TipRanks
Lineage Cell Therapeutics’ Earnings Call: Progress Amid Challenges - TipRanks
Lineage Cell Therapeutics, Inc. (AMEX:LCTX) Q4 2024 Earnings Call Transcript - Insider Monkey
Beyond The Numbers: 7 Analysts Discuss Lineage Cell Therapeutics Stock - Benzinga
Lineage Cell Therapeutics Inc (LCTX) Q4 2024 Earnings Call Highlights: Strategic Advances and ... - Yahoo Finance
Earnings call transcript: Lineage Cell’s Q4 2024 results show revenue rise By Investing.com - Investing.com South Africa
Lineage Cell Therapeutics earnings beat by $0.01, revenue topped estimates - Investing.com Canada
Lineage Cell Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update - BioSpace
Earnings call transcript: Lineage Cell’s Q4 2024 results show revenue rise - Investing.com India
Lineage Cell Therapeutics shares surge 6.8% on positive OpRegen data By Investing.com - Investing.com South Africa
Lineage Cell Therapeutics shares surge 6.8% on positive OpRegen data - Investing.com
Lineage Cell Reports Q4 Revenue Growth, FDA Breakthrough Status for Eye Treatment - StockTitan
Lineage Cell Therapeutics, Inc. to Host Earnings Call - ACCESS Newswire
How Will Lineage Cell Therapeutics Inc (AMEX: LCTX) Look After It Drops -203.77% From Its Highs? - Marketing Sentinel
Lineage Cell Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update on March 10, 2025 - BioSpace
Lineage Cell Therapeutics Inc (LCTX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.63%
자본화:
|
볼륨(24시간):